Abstract
This chapter addresses psychopharmacology, namely the pharmacology of so-called higher brain functions, with a focus on treatments for conditions associated with stress. It is provided here for information purposes only and is not a substitute for official medical or regulatory body guidelines and documents.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., et al. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28(5), 403–439.
Buclin, T., Thoma, Y., Widmer, N., André, P., Guidi, M., Csajka, C., & Decosterd, L. A. (2020). The steps to therapeutic drug monitoring: A structured approach illustrated with imatinib. Frontiers in Pharmacology, 11, 177.
Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: Definitions, diagnosis, and management. The Lancet, 356(9237), 1255–1259.
Estrela, M., Herdeiro, M. T., Ferreira, P. L., & Roque, F. (2020). The use of antidepressants, anxiolytics, sedatives and hypnotics in Europe: Focusing on mental health care in Portugal and prescribing in older patients. International Journal of Environmental Research and Public Health, 17(22), 8612.
Everly, G. S., & Lating, J. M. (2013). A clinical guide to the treatment of the human stress response (4th ed.). Springer.
Hiemke, C., Baumann, P., Bergemann, N., Conca, A., Dietmaier, O., Egberts, K., et al. (2011). AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry, 21(06), 195–235.
HUG. (2015). Guide pour l’emploi des psychotropes d’usage courant. Hôpitaux Universitaires.
Lapeyre-Mestre, M. (2013). Addiction médicamenteuse: quelles données pour évaluer et prévenir ? Psychotropes, 19, 65–80.
Papakostas, G. I., Thase, M. E., Fava, M., Nelson, J. C., & Shelton, R. C. (2007). Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biological Psychiatry, 62(11), 1217–1227.
Stroup, T. S., & Gray, N. (2018). Management of common adverse effects of antipsychotic medications. World Psychiatry, 17(3), 341–356.
WHO. (2015). WHO pharmacovigilance indicators: A practical manual for the assessment of pharmacovigilance systems. World Health Organization.
Zopf, Y., Rabe, C., Neubert, A., Hahn, E. G., & Dormann, H. (2008). Risk factors associated with adverse drug reactions following hospital admission. Drug Safety, 31(9), 789–798.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Fauquet-Alekhine, P., Granry, JC. (2023). Pharmacology for Stress. In: Fauquet-Alekhine, P., Erskine, J. (eds) The Palgrave Handbook of Occupational Stress. Palgrave Macmillan, Cham. https://doi.org/10.1007/978-3-031-27349-0_23
Download citation
DOI: https://doi.org/10.1007/978-3-031-27349-0_23
Published:
Publisher Name: Palgrave Macmillan, Cham
Print ISBN: 978-3-031-27348-3
Online ISBN: 978-3-031-27349-0
eBook Packages: Behavioral Science and PsychologyBehavioral Science and Psychology (R0)